Regeneron Pharmaceuticals Inc. (REGN)
REGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | REGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1991 |
| SEC CIK | 0000872589 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NY |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.3B |
| Net income | $4.5B |
| Operating income | $3.6B |
| Net margin | 31.4% |
| Operating margin | 24.9% |
| Revenue growth | +1.0% |
| Cash | $3.1B |
| Total assets | $40.6B |
| P/E (computed) | 21.9× |
| P/S (computed) | 6.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $3.7B cash; operating cash flow $1.2B a quarter. | Report 2026-09-30 |
| Shares outstanding | 103,447,859 (2026-10-31); 105,099,464 a year earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Florham Park, New Jersey, United States | PCAOB Form AP 2026-02-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $12.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $5.1B | $1.9B | $1.8B | $3.7B | $2.0B | $16.9B | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $4.3B | $1.3B | $813.0M | $2.5B | $2.0B | $15.5B | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $3.6B | $727.2M | $1.1B | $3.0B | $2.0B | $14.9B | 10-Q 2026-04-29 |
| Q4 2025 2025-12-31 | $3.9B | $844.6M | $1.2B | $3.1B | $2.0B | $14.3B | 10-K 2026-02-04 |
| Q3 2025 2025-09-30 | $3.8B | $1.5B | $1.6B | $2.5B | $2.0B | $14.2B | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $3.7B | $1.4B | $1.1B | $2.0B | $2.0B | $14.2B | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $3.0B | $808.7M | $1.0B | $3.1B | $2.0B | $14.1B | 10-Q 2026-04-29 |
| Q4 2024 2024-12-31 | $3.8B | $917.7M | $1.3B | $2.5B | $2.0B | $14.2B | 10-K 2026-02-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2024-10-31 |
| Latest annual report | 10-K | 2026-02-04 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-10-30 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.7% |
| 1 month | +26.9% |
| 3 months | +18.5% |
| Year to date | +23.8% |
| 1 year | +37.5% |
| From 52-week high | -1.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GSK | GSK plc | $50.41 | -0.08% | $102.0B |
| SNY | Sanofi ADS | $48.39 | +0.04% | $118.0B |
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| TAK | Takeda Pharmaceutical Company Limited | $21.59 | +0.75% | $68.2B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier